Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897
N/A
N/A
Female
Breast Cancer
Trial Information
Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897
OBJECTIVES:
- Determine if polymorphisms resulting in greater activation of cyclophosphamide (CYP2B6,
CYP3A4, and CYP3A5) are associated with disease-free survival and treatment toxicities
in women with breast cancer.
- Determine if polymorphisms resulting in less production of quinone-related oxidative
damage of doxorubicin hydrochloride (NQO1, NQO2, NOS2, NOS3, CBR3) are associated with
disease-free survival and treatment toxicities in these patients.
OUTLINE: This is a multicenter study.
Tissue samples archived on clinical trial SWOG-8897 are genotyped for polymorphisms in the
CYP3A4, CYP3A5, CYP2B6, NQO1, NQO2, NOS2, NOS3, and CBR3 genes by matrix-assisted laser
desorption ionization-time-of-flight mass spectrometry. Variant alleles are correlated with
patient outcome.
PROJECTED ACCRUAL: A total of 1,577 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of breast cancer
- Node-negative breast cancer
- Enrolled on clinical trial SWOG-8897
- Archived tissue from patients with normal lymph nodes in the low-risk group
receiving no treatment and those in the intermediate group receiving treatment
- Hormone receptor status known
PATIENT CHARACTERISTICS:
- Female
- Pre- or post-menopausal
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Differences in outcome according to common variant alleles
Safety Issue:
No
Principal Investigator
Christine B. Ambrosone, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Roswell Park Cancer Institute
Authority:
United States: Federal Government
Study ID:
CDR0000529126
NCT ID:
NCT00896623
Start Date:
December 2006
Completion Date:
Related Keywords:
- Breast Cancer
- stage I breast cancer
- stage II breast cancer
- Breast Neoplasms
Name | Location |
|---|
